000705 Zhejiang Zhenyuan Share
- 7.57
- +0.08+1.07%
Zhejiang Zhenyuan Share News
Zhejiang Zhenyuan (000705.SZ) plans to pay 0.6 yuan for every 10 shares in 2023, excluding interest on June 7
Zhejiang Zhenyuan (000705.SZ) issued an announcement. The company's 2023 equity distribution plan is: to all shares...
Zhejiang Zhenyuan (000705.SZ): Zhenyuan Pharmaceutical plans to acquire 100% of the shares of two wholly-owned subsidiaries of Zhenyuan Chemical and Zhenyuan Supply Chain
Gelonghui, May 20 | Zhejiang Zhenyuan (000705.SZ) announced that the second interim meeting of the 11th board of directors of the company in 2024 reviewed and passed the “Proposal on the Wholly-owned Subsidiary Zhenyuan Pharmaceutical to Acquire 100% Shaoxing Zhenyuan Pharmaceutical Management Co., Ltd. (hereinafter referred to as “Zhenyuan Pharmaceutical”) and Zhejiang Zhenyuan Pharmaceutical Supply Chain, a wholly-owned subsidiary, agreed to acquire Shaoxing Zhenyuan Medical Device Chemical Reagent Co., Ltd. (hereinafter referred to as “Zhenyuan Pharmaceutical”) and Zhejiang Zhenyuan Pharmaceutical Supply Chain Chain Management Co., Ltd. (below
Zhejiang Zhenyuan (000705.SZ): The subsidiary Zhenyuan Biotech is building a production line for histidine and other products, which is expected to be tested by the end of this year
Gelonghui, May 7 | Zhejiang Zhenyuan (000705.SZ) said on the investor interactive platform that the company's subsidiary Zhenyuan Biotech is building production lines for histidine, levodopa, tyrosine and other products, which are expected to be put into trial production by the end of this year and officially put into production in 2025.
Zhejiang Zhenyuan (000705.SZ): Net profit of 19.245.99 million yuan in the first quarter increased 3.67% year-on-year
Gelonghui, April 29丨Zhejiang Zhenyuan (000705.SZ) released its report for the first quarter of 2024. Operating income for the reporting period was 1,045 billion yuan, down 4.87% year on year; net profit attributable to shareholders of listed companies was 19.245.99 million yuan, up 3.67% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 18.5337 million yuan, up 2.16% year on year; basic earnings per share were 0.0576 yuan
Zhejiang Zhenyuan (000705.SZ): Proposed capital increase of no more than 495 million yuan
Gelonghui, April 29丨Zhejiang Zhenyuan (000705.SZ) announced that the company plans to issue shares to specific targets to raise a total of no more than 495 million yuan. It is used for Zhejiang Zhenyuan Biotechnology Co., Ltd.'s biotargeted synthesis of 2,400 tons of histidine, 1,000 tons of levodopa, 1,000 tons of tyrosine and other series of products in the Shangyu Industrialization Base Construction Project and Zhejiang Zhenyuan Pharmaceutical Co., Ltd.'s API agglomeration upgrade project.
Zhejiang Zhenyuan (000705.SZ): Net profit for 2023 increased 4.79% to 81.6426 million yuan, plan to pay 10.0.6 yuan
Gelonghui, March 21丨Zhejiang Zhenyuan (000705.SZ) announced its 2023 annual report. In 2023, the company achieved operating income of 4.106 billion yuan, a year-on-year decrease of 0.94%; net profit attributable to shareholders of listed companies was 81.6426 million yuan, up 4.79% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 782,125 million yuan, an increase of 14.40% year on year; basic earnings per share of 0.24 yuan; it is intended to distribute a cash dividend of 0.60 yuan (tax included) to all shareholders for every 10 shares.
Zhejiang Zhenyuan (000705.SZ): No in-depth business cooperation with Wahaha Group
Gelonghui March 15 丨 Some investors asked Zhejiang Zhenyuan (000705.SZ) on the investor interactive platform, “Has your company developed in-depth business cooperation with Zhejiang Wahaha Group?” The company replied that the company and Wahaha Group have not developed further business cooperation.
Zhejiang Zhenyuan (000705.SZ): Holds 0.11% of Zhejiang Wahaha Industrial Co., Ltd.
Gelonghui March 8 丨 Zhejiang Zhenyuan (000705.SZ) said on the investor interactive platform that the company holds 0.11% of Zhejiang Wahaha Industrial Co., Ltd. The company is unaware of Wahaha Group's acquisition or listing plans.
Zhejiang Zhenyuan (000705.SZ): Plans to raise no more than 800 million yuan in additional capital for Zhenyuan Pharmaceutical raw material agglomeration and upgrading projects, etc.
Gelonghui, Feb. 28, 丨 Zhejiang Zhenyuan (000705.SZ) announced the 2024 stock issuance plan. The number of shares issued to specific targets is determined by dividing the total amount of capital raised by the issuance price. At the same time, the number of shares issued does not exceed 30% of the total share capital of the company before the issuance, that is, no more than 100,236,985 shares (including the number of shares), and is subject to the registration approval documents of the China Securities Regulatory Commission for this offering. The distribution targets no more than 35 specific targets, including Zhenyuan Health Group, the controlling shareholder of the company. All issuers subscribe in cash
Zhejiang Zhenyuan (000705.SZ): No plans to enter the weight loss drug market
Gelonghui Feb. 27丨Zhejiang Zhenyuan (000705.SZ) said on the investor interactive platform that the company has no diet drug-related products and has no plans to enter the weight loss drug market.
Are Zhejiang Zhenyuan Share Co.,Ltd.'s (SZSE:000705) Mixed Financials Driving The Negative Sentiment?
Zhejiang Zhenyuan ShareLtd (SZSE:000705) has had a rough month with its share price down 34%. It seems that the market might have completely ignored the positive aspects of the company's fundamental
Zhejiang Zhenyuan (000705.SZ): The patents obtained are all existing processes, backup processes and alternative molecules, or quality control methods, impurity identification, etc. of currently produced or developed varieties
Gelonghui, January 18 | Zhejiang Zhenyuan (000705.SZ) said on the investor interactive platform that the patents obtained by the company are all existing processes, backup processes and alternative molecules, or quality control methods, impurity identification, etc. of varieties currently in production or development.
Zhejiang Zhenyuan (000705.SZ): We have approval for the production of Huperzine A tablets, but this product is not currently being produced
Gelonghui January 15 丨 An investor asked Zhejiang Zhenyuan (000705.SZ) on the investor interactive platform, “What is the effectiveness and sales status of huxerine nail tablets produced by your company to treat Alzheimer's syndrome? Are there any new drugs developed to treat Alzheimer's syndrome?” The company replied that the company has approval for the production of huxerine A tablets, but it is currently not producing this product, and there are no research plans for related new drugs.
Optimistic Investors Push Zhejiang Zhenyuan Share Co.,Ltd. (SZSE:000705) Shares Up 26% But Growth Is Lacking
Zhejiang Zhenyuan Share Co.,Ltd. (SZSE:000705) shares have continued their recent momentum with a 26% gain in the last month alone. The last 30 days bring the annual gain to a very sharp 39%. Sin
Zhejiang Zhenyuan (000705.SZ): Currently, it mainly produces antibiotic raw materials such as nystatin, roxithromycin, sisomicin sulfate, netimicin sulfate, and ceftaxime hydrochloride
Gelonghui, January 8 | Zhejiang Zhenyuan (000705.SZ) said on the investor interactive platform that the company currently mainly produces antibiotic raw materials such as nystatin, roxithromycin, sisomicin sulfate, netimicin sulfate, and ceftalamate hydrochloride, which are used to produce corresponding antibiotic formulation products.
Zhejiang Zhenyuan (000705.SZ): No pension programs have been carried out
Gelonghui January 8 丨 Zhejiang Zhenyuan (000705.SZ) said on the investor interactive platform that the company has not carried out pension projects.
Zhejiang Zhenyuan (000705.SZ): The company did not use half-summer Chinese herbal medicine to make synthetic organisms
Gelonghui January 8 | Zhejiang Zhenyuan (000705.SZ) said on the investor interactive platform that the international standard “Traditional Chinese Medicine - Half Summer” was officially released on November 2, 2023. The company does not use Banxia Chinese herbal medicine to make synthetic organisms.
Zhejiang Zhenyuan (000705.SZ): Plans to transfer the pharmaceutical wholesale business to Zhenyuan Pharmaceutical and increase its capital by 67.1 million yuan
Gelonghui, December 26 | Zhejiang Zhenyuan (000705.SZ) announced that the 11th interim meeting of the company's board of directors in 2023 reviewed and passed the “Proposal on Transferring the Company's Pharmaceutical Wholesale Business to the Wholly-owned Subsidiary Zhenyuan Pharmaceutical and increasing its capital”: it was agreed to transfer all of the company's pharmaceutical wholesale business to the wholly-owned subsidiary Shaoxing Zhenyuan Pharmaceutical Management Co., Ltd. (“Zhenyuan Pharmaceutical”), and Zhenyuan Pharmaceutical undertakes the company's existing pharmaceutical wholesale business and personnel. At the same time, the capital of Zhenyuan Pharmaceutical was increased by 67.1 million yuan with its own capital to support the development of Zhenyuan Pharmaceutical's pharmaceutical wholesale business. This capital increase is complete
Zhejiang Zhenyuan (000705.SZ): Zhenyuan Chain plans to acquire 100% of Tongyuan Health Management's shares for 35.3044 million yuan
Gelonghui, December 26, 丨 Zhejiang Zhenyuan (000705.SZ) announced that the 11th interim meeting of the company's board of directors in 2023 reviewed and passed the “Proposal on the Holding Subsidiary Zhenyuan Chain to Acquire 100% of the Shaoxing Tongyuan Health Management Co., Ltd.” (“Zhenyuan Chain”), the holding subsidiary, agreed to acquire 100% of the shares of Shaoxing Tongyuan Health Management Co., Ltd. (“Tongyuan Health Management”) held by the company in accordance with the purchase price of 35.304,400 yuan, and authorized the management team to complete specific matters.
Zhejiang Zhenyuan ShareLtd (SZSE:000705) Is Experiencing Growth In Returns On Capital
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. In a perfect world, we'd like to see a company investing more capital into its business and idea
Analysis
Price Target
No Data
